Search

Background: Human epidermal growth factor receptor 2 (HER2) is a significant driver gene among breast cancer (BC) and a gene locus for anti-HER2 targeted therapy. Amplification of the HER2 gene often indicates poor prognosis. We aimed to evaluate the impact of low HER2 expression in response to neoadjuvant chemotherapy (NAC) and survival outcomes in early luminal BC.Methods:We conducted this retrospective cohort study on 100 female patients with early luminal BC with low HER2 expression treated using NAC. The primary endpoint was to evaluate the pathological response, secondary endpoint was to evaluate clinicopathological criteria, disease-free survival (DFS) as well as overall survival (OS). Results: Invasive ductal carcinoma (IDC) was the commonest pathological type (76.0%), and Grade II was the commonest (73.0). T2 was the commonest (78.0%). N2 was the commonest (39.0%), stage II was the commonest (48%), 5-years DFS was (79.7%) with average (30.0±25.52) months while 5-years OS rate was (79%) with the average (38.82±27.54) months, 16% had pathological complete response (pCR) and 84% hadn't pCR with statistically significant difference in distribution. A statistically significant relation was revealed between the pCR and pathological type (P value= <0.002), pCR was significantly associated with 5 years of DFS (P <0.001) and OS (P <0.001). Conclusions: Our results did not show a significant impact of low HER2 on pCR, DFS, or OS, but showed low pCR achievement especially as most were HR-positive. Low HER2 may be a distinct biological entity that requires further research with a prospective nature and adequate population. With the new HER2 targeting ADCs which prove beneficial in low HER-2 patients' preparatory activity data, patients with low HER2 may considered a special population subset for finding new treatment options to NAC to improve BC results. [ABSTRACT FROM AUTHOR]

Background: Sorafenib is the standard treatment for patients with hepatocellular carcinoma (HCC) with advanced stage disease. An accurate prediction model is important to ascertain the prognosis of HCC patients treated with sorafenib. This study aimed to predict the outcome of HCC patients treated with sorafenib using ACLR and HALP scores. Methods: This Observational Retrospective Cohort Study was conducted on 110 Patients with HCC patients from January 2015 to December 2022 at Medical Oncology Department, Faculty of Medicine, Zagazig University. Results: HALP and ACLR score were significantly associated with treatment outcome among HCC patients treated with sorafenib. HALP was a predictor for treatment outcome among HCC patients treated with sorafenib at cut off point of 42.9 with sensitivity of 75.7% and specificity of 86.3%. ACLR was a predictor for treatment outcome among HCC patients treated with sorafenib at cut off point of 75.6 with sensitivity of 78.4% and specificity of 82.2%. High HALP score indicates better prognosis with a cut off of 42.9. Low ACLR indicates better prognosis with a cut of 75.6. Conclusion: Both HALP and ACLR scores can be used as valid prognostic scores for independently predicting the overall prognosis in HCC patients treated with Sorafenib. Having a low HALP score indicates worse prognosis, while, our results showed that the cut off for ACLR 75.6 .. but high and low score didn't show any significance in predicting the PFS or OS but they show significant sensitivity and specificity. [ABSTRACT FROM AUTHOR]